Moxifloxacin Stada

Moxifloxacin, the active ingredient in Moxifloxacin Stada, is a fluoroquinolone antibiotic presented as an oral dosage form for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and soft‑tissue infections in adults.

GNH USA supplies Moxifloxacin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat infections caused by susceptible bacteria. - Community‑acquired pneumonia: eradicates the causative pathogens and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and bacterial load, relieving symptoms. - Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents disease progression. - Skin and soft‑tissue infections: treats mild to moderate infections caused by susceptible organisms.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal pain: cramping or discomfort in the stomach area. - Dyspepsia: indigestion or heartburn.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon break, especially in the Achilles. - QT interval prolongation: may lead to serious cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema, or skin rash. - Clostridioides difficile infection: colitis presenting with severe diarrhea. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Peripheral neuropathy: tingling, numbness, or weakness in extremities.

Before prescribing Moxifloxacin, clinicians should consider several safety aspects. - Assess renal function: adjust therapy in patients with severe renal impairment. - Review cardiac history: monitor QT interval in patients with known arrhythmias. - Evaluate tendon health: avoid use in individuals with recent tendon injury or chronic tendon disorders. - Check for hypersensitivity: discontinue immediately if allergic signs appear. - Use under medical supervision: ensure appropriate indication and microbiological confirmation. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Moxifloxacin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increased risk of cardiac arrhythmia. - Concurrent use of systemic corticosteroids or NSAIDs: heightened risk of tendon rupture. - Antacids or supplements containing aluminum, magnesium, calcium, or iron: markedly reduces oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR regularly. - Theophylline: possible increase in plasma concentration; observe for signs of toxicity.